Comparative Pharmacology
Head-to-head clinical analysis: DIMETANE DX versus MUCINEX DM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIMETANE DX versus MUCINEX DM.
DIMETANE-DX vs MUCINEX DM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dimetane-DX contains brompheniramine (first-generation antihistamine) and dextromethorphan (NMDA receptor antagonist and sigma-1 agonist). Brompheniramine antagonizes histamine at H1 receptors, reducing allergic symptoms; dextromethorphan suppresses cough by acting on the cough center in the medulla oblongata via NMDA receptor antagonism and sigma-1 receptor activation.
Guaifenesin increases respiratory tract fluid secretion to reduce mucus viscosity; dextromethorphan acts on sigma-1 receptors and NMDA receptor antagonism to suppress cough reflex.
Adults and children ≥12 years: One tablet (brompheniramine 4 mg, dextromethorphan 10 mg, phenylephrine 10 mg) orally every 4 hours as needed, not to exceed 4 doses in 24 hours.
One tablet (guaifenesin 600 mg / dextromethorphan HBr 30 mg) orally every 12 hours, not to exceed 2 tablets in 24 hours.
None Documented
None Documented
Brompheniramine: 25-30 hours; guaifenesin: 1 hour; dextromethorphan: 2-4 hours (CYP2D6 extensive metabolizers) or 20-40 hours (poor metabolizers).
Guaifenesin: 1-3 hours. Dextromethorphan: 3-30 hours depending on CYP2D6 phenotype; extensive metabolizers 3-8 hours, poor metabolizers 15-30 hours.
Renal: 50-70% (brompheniramine) as metabolites and unchanged drug; guaifenesin metabolites primarily renal; dextromethorphan and metabolites renal. Biliary/fecal: minor.
Guaifenesin: renal (primarily as inactive metabolites, <1% unchanged). Dextromethorphan: renal (as unchanged drug and metabolites, including dextrorphan). Approximately 80% eliminated in urine as metabolites.
Category C
Category C
Antitussive Combination
Expectorant/Antitussive Combination